報價延遲最少15分鐘:2026/04/21 18:16 EDT
盤後時段
|
||||
|
9.47 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.47
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.18/-1.03
|
|
企業價值
887.28M
|
| 資產負債 |
|
每股賬面淨值
1.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
67.48M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases. |
